Profluent Bio vs Microbiotica

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (37 vs 39)
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile
Microbiotica logo

Microbiotica

EmergingBioTech

Microbiome Therapeutics

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.

AI VisibilityBeta
Overall Score
D39
Category Rank
#1 of 2
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
47
Perplexity
43
Gemini
47

About

Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.

Full profile

AI Visibility Head-to-Head

37
Overall Score
39
#1
Category Rank
#1
69
AI Consensus
75
up
Trend
up
45
ChatGPT
47
35
Perplexity
43
38
Gemini
47
37
Claude
42
31
Grok
37

Key Details

Category
AI Protein Design
Microbiome Therapeutics
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Profluent Bio
AI Protein Design
Only Microbiotica
Microbiome Therapeutics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.